Page last updated: 2024-11-07

5-hydroxymethylomeprazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-hydroxymethylomeprazole: metabolite of omeprazole [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5'-hydroxyomeprazole : A sulfoxide that is omeprazole in which one of the methyl hydrogens at position 5 on the pyridine ring is substituted by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID119560
CHEMBL ID3527071
CHEBI ID63840
SCHEMBL ID3058978
MeSH IDM0142927

Synonyms (28)

Synonym
hydroxyomeprazole
AKOS005146284
92340-57-3
FT-0651053
[4-methoxy-6-[(6-methoxy-1h-benzimidazol-2-yl)sulfinylmethyl]-5-methylpyridin-3-yl]methanol
4-methoxy-6-(((5-methoxy-1h-benzimidazol-2-yl)sulfinyl)methyl)-5-methyl-3-pyridinemethanol
5-hydroxymethylomeprazole
3-pyridinemethanol, 4-methoxy-6-(((5-methoxy-1h-benzimidazol-2-yl)sulfinyl)methyl)-5-methyl-
5-hydroxy omeprazole
5-methoxy-2-(((4-methoxy-3-methyl-5-hydroxymethyl-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
(4-methoxy-6-{[(5-methoxy-1h-benzimidazol-2-yl)sulfinyl]methyl}-5-methylpyridin-3-yl)methanol
5'-hydroxyomeprazole
CHEBI:63840 ,
SCHEMBL3058978
5-hydroxyomeprazole
CHEMBL3527071
{4-methoxy-6-[(6-methoxy-1h-1,3-benzodiazole-2-sulfinyl)methyl]-5-methylpyridin-3-yl}methanol
5-hydroxyomeprazole, analytical standard
(4-methoxy-6-((5-methoxy-1h-benzo[d]imidazol-2-ylsulfinyl)methyl)-5-methylpyridin-3-yl)methanol
{4-methoxy-6-[(6-methoxy-1h-benzimidazole-2-sulfinyl)methyl]-5-methylpyridin-3-yl}methanol
DTXSID50919234
1189882-58-3
5-hydroxy omeprazole-(pyridyl)-d3
Q27132844
AS-6126
AKOS037645535
5-hydroxy omeprazole (~5per cent triethylamine as stabilizer)
PD057530

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Derived pharmacokinetic constants of intact omeprazole were within the range of those reported in healthy individuals."( Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.
Andersson, T; Bodemar, G; Larsson, R; Naesdal, J; Regårdh, CG; Skånberg, I; Walan, A, 1986
)
0.27
"The pharmacokinetic profile of omeprazole was examined in 27 healthy Japanese volunteers, and the results were analyzed in relation to genotype for the two mutations, CgammaP2C19m1 in exon 5 and CgammaP2C19m2 in exon 4, associated with the poor metabolizer phenotype."( Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
Amamoto, T; Higuchi, S; Ieiri, I; Irie, S; Kimura, M; Kubota, T; Mamiya, K; Nakamura, K; Nakano, S; Urae, A; Wada, Y; Yoshioka, S, 1996
)
0.29
" Pharmacokinetic parameters were obtained by noncompartmental analysis."( The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa, Y; Sasaki, M; Takahata, T; Tateishi, T; Yasui-Furukori, N, 2005
)
0.33
" The present method was successfully applied to a chiral pharmacokinetic study of omeprazole in human volunteers with different CYP2C19 genotypes."( Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes.
Shiohira, H; Tateishi, T; Uno, T; Yasui-Furukori, N, 2011
)
0.37
" The present study was conducted to evaluate the pharmacokinetic parameters of omeprazole after a single oral administration to a random Iranian population."( Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study.
Keyhanfar, F; Kobarfard, F; Motevalian, M; Noubarani, M, 2012
)
0.38
" A single oral dose, open-label, non-controlled, pharmacokinetic study of omeprazole was conducted in healthy young/premenopausal females (n = 16)."( Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle.
Ahmad, L; Iqbal, Z; Nasir, F; Nazir, S; Shah, Y, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The slight dose-dependency of the bioavailability of the solution is considered to be of no or limited clinical relevance."( Pharmacokinetics of various single intravenous and oral doses of omeprazole.
Andersson, T; Cederberg, C; Regårdh, CG; Skånberg, I, 1990
)
0.28
" The median bioavailability was 39% (25-117%) and the median systemic plasma clearance was 624 ml/min (range of 59-828 ml/min)."( The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
Andersson, T; Lagerström, PO; Lundborg, P; Regårdh, CG; Skånberg, I, 1990
)
0.28
" The relative bioavailability of omeprazole can be accurately assessed using this multiple-dose study design."( High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.
Edwards, DJ; Kovacs, P; Lalka, D; Scheiwe, WM; Stoeckel, K, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" When a single esomeprazole dose and multiple dosing were compared, the low contribution of CYP2C19 to the elimination of esomeprazole decreased further by 50%."( Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G, 2005
)
0.33
" The results of this study will be useful for drug dosage recommendations in Colombian mestizos."( Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
Beltrán, L; Henao, J; Isaza, C; Martínez, JH; Sepúlveda Arias, JC, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450
Omeprazole and Esomeprazole Pathway, Pharmacokinetics38

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1210419Ratio of AUC for compound to omeprazolein human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.92)18.7374
1990's15 (28.85)18.2507
2000's20 (38.46)29.6817
2010's15 (28.85)24.3611
2020's1 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.58 (24.57)
Research Supply Index4.28 (2.92)
Research Growth Index5.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (31.48%)5.53%
Reviews1 (1.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]